Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2014 | 12-2006 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 29,374 | 2,656 | N/A |
| Marketable Securities | 3,768 | N/A | N/A |
| Receivables | 1,697 | N/A | N/A |
| Other current assets | 2,535 | 0 | 0 |
| TOTAL | $38,286 | $2,730 | $N/A |
| Non-Current Assets | |||
| PPE Net | 348 | 162 | N/A |
| Other Non-Current Assets | 20 | 38 | 0 |
| TOTAL | $368 | $200 | $N/A |
| Total Assets | $38,654 | $2,930 | $N/A |
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 176 | 345 | 0 |
| Accrued Expenses | 2,347 | 713 | N/A |
| TOTAL | $2,523 | $1,058 | $N/A |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 27 | 0 | 0 |
| TOTAL | $27 | $N/A | $N/A |
| Total Liabilities | $2,550 | $1,058 | $N/A |
| Shareholders' Equity | |||
| Common Shares | N/A | 811 | N/A |
| Retained earnings | -23,579 | -12,284 | N/A |
| Other shareholders' equity | 58,310 | 13,345 | 0 |
| TOTAL | $36,104 | $1,872 | $N/A |
| Total Liabilities And Equity | $38,654 | $2,930 | $0 |